ABIVAX Société Anonyme (ABVX)
| Market Cap | 8.27B |
| Revenue (ttm) | 7.07M |
| Net Income (ttm) | -229.46M |
| Shares Out | 63.47M |
| EPS (ttm) | -3.63 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,422,574 |
| Open | 103.00 |
| Previous Close | 100.90 |
| Day's Range | 103.00 - 112.50 |
| 52-Week Range | 4.77 - 112.50 |
| Beta | -0.11 |
| Analysts | Buy |
| Price Target | 110.36 (-0.03%) |
| Earnings Date | Aug 11, 2025 |
About ABVX
ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate includes obefazimod that is in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis, as well as in Phase 2b clinical trial to treat patients with Crohn’s disease. The company was incorporated in 2013 and is headquartered in Paris, France. [Read more]
Financial Performance
In 2024, ABIVAX Société Anonyme's revenue was 10.79 million, an increase of 135.94% compared to the previous year's 4.57 million. Losses were -176.24 million, 19.3% more than in 2023.
Financial numbers in EUR Financial StatementsAnalyst Summary
According to 11 analysts, the average rating for ABVX stock is "Buy." The 12-month stock price target is $110.36, which is a decrease of -0.03% from the latest price.
News
Abivax: Phase 3 Data Was A Home Run, Top Target For M&A In 2026
Abivax delivered outstanding phase 3 results for obefazimod in ulcerative colitis, with a 16.4% placebo-adjusted clinical remission rate. ABVX's safety profile is superior to JAK inhibitors and S1Ps, ...
Abivax: Betting Big On The Next Inflammatory Bowel Disease Blockbuster
ABIVAX Société Anonyme [NASDAQ: ABVX] is rated a Strong Buy with a $105 price target, driven by Obefazimod's best-in-class potential for ulcerative colitis (UC). ABVX's Obefazimod shows robust efficac...
ABIVAX Société Anonyme (ABVX) Shareholder/Analyst Call Transcript
ABIVAX Société Anonyme (NASDAQ:ABVX) Shareholder/Analyst Call October 6, 2025 9:00 AM EDT Company Participants Patrick Malloy - Senior Vice President of Investor Relations Marc M. de Garidel - CEO & ...
Why Is Abivax Stock Trading Higher On Monday?
Abivax SA (NASDAQ:ABVX) shared additional clinical data on Monday for obefazimod at the United European Gastroenterology (UEG) Meeting.
Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Trial Results with Updated Safety Data
Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Trial Results with Updated Safety Data 50 mg once-daily dose of obefazimod led to a pooled 16.4% (p
Abivax Announces Acceptance of Additional Late-Breaking Abstract from the ABTECT Phase 3 Induction Trials to be Presented at 2025 United European Gastroenterology (UEG) Meeting
Abivax Announces Acceptance of Additional Late-Breaking Abstract from the ABTECT Phase 3 Induction Trials to be Presented at 2025 United European Gastroenterology (UEG) Meeting
Abivax Announces Presentation of Late-Breaking Abstract for Obefazimod from the ABTECT Phase 3 Induction Trials at 2025 United European Gastroenterology (UEG) Meeting
Abivax Announces Presentation of Late-Breaking Abstract for Obefazimod from the ABTECT Phase 3 Induction Trials at 2025 United European Gastroenterology (UEG) Meeting
Abivax to Join CAC Mid 60 and SBF 120 Indices Following Euronext Paris Annual Review
Abivax to Join CAC Mid 60 and SBF 120 Indices Following Euronext Paris Annual Review PARIS, France, September 12, 2025, 5:45 p.m. CEST – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq – ABVX)...
Abivax Presents First Half 2025 Financial Results
Abivax Presents First Half 2025 Financial Results PARIS, France, September 8, 2025, 10:00 p.m. CEST – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq – ABVX) (“Abivax” or the “Company”), a cli...
How Hedge Funds Won Big on an Obscure Drugmaker
Results of a Paris company's late-stage drug trial helped turn things around for healthcare-focused funds, which struggled in the first half of the year.
2 Logical Mid-Cap Biotech Buyout Targets
There have been some significant acquisitions in the mid-cap biotech space over the past couple of months. In today's column, I highlight two mid-cap biotech names that should have bright futures on t...
Abivax Announces Closing of $747.5 Million Public Offering
Abivax Announces Closing of $747.5 Million Public Offering PARIS, France, July 28, 2025 – 10:15 p.m. (CEST) – Abivax SA (Euronext Paris: FR0012333284 – ABVX) (“Abivax” or the “Company”), a clinical-st...
Abivax Announces Full Exercise of Underwriters' Option to Purchase Additional ADSs, Bringing Gross Proceeds of Offering to $747.5M (€637.5M)
Abivax Announces Full Exercise of Underwriters' Option to Purchase Additional ADSs, Bringing Gross Proceeds of Offering to $747.5M (€637.5M)
Abivax: Positive Obefazimod Induction Data Leads To Next 44-Week Maintenance Trial Catalyst
Abivax shares surged 500% after positive phase 3 results for obefazimod in moderate-to-severe ulcerative colitis, achieving significant clinical remission at 8 weeks induction period. Both ABTECT-1 an...
Abivax announces trading resumption of its ordinary shares on Euronext Paris
Abivax announces trading resumption of its ordinary shares on Euronext Paris PARIS, France, July 24, 2025 – 02:30 p.m. (CEST) – Abivax SA (Euronext Paris: FR0012333284 – ABVX) (“Abivax” or the “Compan...
Abivax Announces Pricing of $650M (€554M) Public Offering of American Depositary Shares
Abivax Announces Pricing of $650M (€554M) Public Offering of American Depositary Shares PARIS, France, July 24, 2025 – 2:30 p.m. (CEST) – Abivax SA (Euronext Paris: FR0012333284 – ABVX) (“Abivax” or t...
Abivax announces temporary trading halt of its ordinary shares on Euronext Paris
Abivax announces temporary trading halt of its ordinary shares on Euronext Paris PARIS, France, July 24, 2025 – 07:30 a.m. (CEST) – Abivax SA (Euronext Paris: FR0012333284 – ABVX) (“Abivax” or the “Co...
Abivax Announces Launch of Public Offering
Abivax Announces Launch of Public Offering PARIS, France, July 23, 2025 – 10:15 p.m. (CEST) – Abivax SA (Euronext Paris: FR0012333284 – ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnolog...
Abivax: Differentiated Phase 3 Data Ignites A Multi-Billion Dollar Opportunity
Obefazimod's strong Phase 3 induction data positions Abivax as a leading UC contender, with a novel mechanism and favorable safety profile. The ABTECT program's robust design and inclusion of hard-to-...
Abivax: Good Entry Point Ahead Of The Mega Catalyst - Phase 3 Data Readout
Abviax's Obefazimod shows promising phase 2b results in ulcerative colitis, with superior safety and efficacy compared to existing treatments, supporting a buy rating. The drug's novel mechanism modul...
Abivax Announces Results of its June 6, 2025 Annual General Meeting
Abivax Announces Results of its June 6, 2025 Annual General Meeting PARIS, France, June 11, 2025, 10:00 p.m. CEST – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq – ABVX) (“Abivax” or the “Co...
Abivax Presents First Quarter 2025 Financial Results
Abivax Presents First Quarter 2025 Financial Results PARIS, France, June 2, 2025, 10:00 p.m. CEST – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq – ABVX) (“Abivax” or the “Company”), a clini...
Biotech Bull Case, ABVX International Interest, JNJ & LLY Options Trades
"You cannot not believe in science," says Tsvetta Kaleynska. She sees biotech companies outperforming in 2025 despite a slow start to the year.
Abivax Announces Completion of Enrollment for the Phase 3 ABTECT Trials in Patients with Moderately to Severely Active Ulcerative Colitis
Abivax Announces Completion of Enrollment for the Phase 3 ABTECT Trials in Patients with Moderately to Severely Active Ulcerative Colitis
Abivax Announces Annual General Meeting Details as Company Advances Toward Key 2025 Value-Driving Milestones
Abivax Announces Annual General Meeting Details as Company Advances Toward Key 2025 Value-Driving Milestones Annual General Meeting scheduled for Friday, June 6, 2025, in Paris, France Phase 3 ABTECT ...